FDA advisory committee votes to add popular peptide BPC-157 to drug compounding list
Summary
An FDA advisory committee voted 8-6, with one abstention, to add the peptide BPC-157 to the drug compounding list. This vote means BPC-157 could become legally available for prescription use after final FDA approval, despite limited data on its safety and effectiveness.Key Facts
- The committee’s vote is non-binding and needs final approval from the FDA.
- BPC-157 is a peptide popular online for claims about healing gut and tissue, but lacks strong human study evidence.
- Peptides like BPC-157 are often bought on black or grey markets without regulation.
- Compounding allows making drugs customized for patients without full FDA approval, using a less strict regulatory path.
- Some committee members think health risks of BPC-157 are low; others worry about safety and misleading impressions of approval.
- Most research on BPC-157 has been done on rodents, not humans.
- Health and Human Services Secretary Robert F. Kennedy Jr. supports peptide use, but there are concerns about conflicts of interest among advisory panel members.
- This is the first peptide among seven being reviewed for potential compounding approval.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
